Chlamydia vaccines: Recent developments and the role of adjuvants in future formulations

Expert Review of Vaccines

Volumn 10, Issue 11, 2011, Pages 1585-1596

  Igietseme, Joseph U ^a,b   Eko, Francis O ^b   Black, Carolyn M ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

adjuvant; Chlamydia; control; delivery; prevention; prophylactic; therapeutic; vaccine

Indexed keywords

AZITHROMYCIN; BACTERIAL VACCINE; BACTERIAL VECTOR; CHLAMYDIA VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DNA PRIMASE; DOXYCYCLINE; ERYTHROMYCIN; FREUND ADJUVANT; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HEPATITIS B VACCINE; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 17; LIVE VACCINE; MIFAMURTIDE; OUTER MEMBRANE PROTEIN A; POLLEN VACCINE; POLLINEX QUATTRO; RESIQUIMOD; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; BORRELIA BURGDORFERI; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIA; CHLAMYDIA PECORUM; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EYE INFECTION; GENITAL TRACT INFECTION; HEALTH CARE COST; HEALTH EDUCATION; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPOTENTIATION; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOID TISSUE; MASS SCREENING; MEMORY CELL; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; T-LYMPHOCYTES;

EID: 80455158288     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.139     Document Type: Review

References (122)

1. Stephens RS, Tam MR, Kuo C-C, Nowinski RC. Monoclonal antibodies to Chlamydia trachomatis: antibody specificities and antigen characterization. J. Immunol. 128, 1083-1089 (1982). (Pubitemid 12188416)
2. Stephens RS, Wagar EA, Schoolnik GK. High-resolution mapping of serovarspecific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J. Exp. Med. 167, 817-831 (1988).
3. Bandea CI, Kubotaa K, Brown TM et al. Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein (omp1). Sex. Transm. Infect. 77, 419-422 (2001). (Pubitemid 33086924)
4. Bush RM, Everett KD. Molecular evolution of Chlamydiaceae. Int. J. Syst. Evol. Microbiol. 51, 203-220 (2001).
5. Schachter J, Stephens RS, Timms P et al. Radical changes to chlamydial taxonomy are not necessary just yet. Int. J. Syst. Evol. Microbiol. 51, 251-253 (2001).
6. Schachter J. Infection and disease epidemiology. In Chlamydia: Intracellular Biology, Pathogenesis, and Immunity. Stephens RS (Ed.). ASM, Washington, DC, USA 139-169 (1999).
7. WHO. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. WHO, Geneva, Switzerland (2001).
8. CDC. Sexually transmitted diseases, treatment guidelines, 2010. MMWR Recomm. Rep. 59(RR-12), 1-110 (2010).
9. Mahdi OS, Byrne GI, Kalayoglu M. Emerging strategies in the diagnosis, prevention and treatment of chlamydial infections. Expert Opin. Ther. Patents 11, 1253-1265 (2001). (Pubitemid 32707659)
10. Schachter J. NAATs to diagnose Chlamydia trachomatis genital infection: a promise still unfulfilled. Expert Rev. Mol. Diagn. 1(2), 137-144 (2001). (Pubitemid 34662822)
11. Thein J, Zhao P, Liu H et al. Does clinical diagnosis indicate chlamydial infection in areas with a low prevalence of trachoma? Ophthalmic Epidemiol. 9, 263-269 (2002). (Pubitemid 34831912)
12. Johnson RE, Newhall WJ, Papp JR et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections - 2002. MMWR Recomm. Rep. 51, 1-40 (2002).
13. Rees E. Treatment of pelvic inflammatory disease. Am. J. Obstet. Gynecol. 138, 1042-1047 (1980).
14. Westrom L, Joesoef R, Reynolds G et al. Pelvic inflammatory inflammatory disease and infertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopy results. Sex. Transm. Dis. 19, 185-192 (1992).
15. Paavonen J, Wolner-Hanssen P. Chlamydia trachomatis: a major threat to reproduction. J. Hum. Reprod. 4, 111-124 (1989). (Pubitemid 19069922)
16. Stamm WE, Guinan ME, Johnson C et al. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N. Engl. J. Med. 310, 545-549 (1984). (Pubitemid 14193092)
17. Schachter J, Osoba AO. Lymphogranuloma venereum. Br. Med. Bull. 39, 151-154 (1983). (Pubitemid 13123223)
18. Mabey D, Peeling RW. Lymphogranuloma venereum. Sex. Transm. Infect. 78, 90-92 (2002). (Pubitemid 34548024)
19. Nieuwenhuis RF, Ossewaarde JM, Gotz HM et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar L2 proctitis in The Netherlands among men who have sex with men. Clin. Infect. Dis. 39, 996-1003 (2004). (Pubitemid 39313456)
20. 20 CDC. Sexually transmitted disease surveillance, 2000. US Department of Health and Human Services, CDC, Atlanta, GA, USA (2001).
21. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr. Opin. HIV AIDS 5, 305-310 (2010).
22. Wilkinson D, Rutherford G. Populationbased interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Databse Syst. Rev. (2), CD001220 (2001).
23. Kilmarx PH, Mock PA, Levine WC. Effect of Chlamydia trachomatis coinfection on HIV shedding in genital tract secretion. Sex. Transm. Dis. 28, 347-348 (2001). (Pubitemid 34163567)
24. Mcclelland RS, Wang CC, Mandaliya K et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 15, 105-110 (2001). (Pubitemid 32055785)
25. Simonetti A, Melo J, de Souza P et al. Immunological's host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor. Microbes Infect. 11, 435-442 (2009).
26. Kumar S, Hammerschlag M. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin. Infect. Dis. 44, 568-576 (2007). (Pubitemid 46233262)
27. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8, 451-461 (1995).
28. Gaillat J. Clinical manifestations of Chlamydia pneumoniae infections. Revue de Med. Interne. 17, 987-999 (1996).
29. Everett KD. Chlamydia and Chlamydiales: more than meets the eye. Vet. Microbiol. 75, 109-126 (2000). (Pubitemid 30411993)
30. Saikku P, Wang SP, Kleemola M et al. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J. Infect. Dis. 151, 832-839 (1985). (Pubitemid 15094599)
31. Rodolaki A, Salinas J, Papp J. Recent advances on ovine chlamydial abortion. Vet. Res. 29, 275-288 (1998). (Pubitemid 28293468)
32. Nietfeld J. Chlamydial infections in small ruminants. Vet. Clin. North Am. Food Anim. Pract. 17, 301-314 (2001).
33. West S. Global elimination of blinding trachoma by 2020: where are we? Ophthalmic Epidemiol. 16, 205 (2009).
34. Brunham R, Rekart M. The arrested immunity hypothesis and the epidemiology of Chlamydia control. Sex. Transm. Dis. 35, 53-54 (2008). (Pubitemid 351619350)
35. Bragina EY, Gomberg MA, Dmitriev GA. Electron microscopic evidence of persistent chlamydial infection following treatment. J. Eur. Acad. Dermatol. Venereol. 15, 405-409 (2001). (Pubitemid 33048754)
36. Byrne GI. Chlamydial treatment failures: a persistent problem? J. Eur. Acad. Dermatol. Venereol 15, 381 (2001). (Pubitemid 33040103)
37. Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, Hudson AP, Zeidler H, Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. 44, 3288-3297 (2000). (Pubitemid 33009485)
38. Miyashita N, Fukano H, Hara H, Yoshida K, Niki Y, Matsushima T. Recurrent pneumonia due to persistent Chlamydia pneumoniae infection. Intern. Med. 41, 30-33 (2002). (Pubitemid 34196206)
39. Rees E, Tait IA, Hobson D, Karayiannis P, Lee N. Persistence of chlamydial infection after treatment for neonatal conjunctivitis. Arch. Dis. Child. 56, 193-198 (1981). (Pubitemid 11105993)
40. Babalola OE, Bage SD. The persistence of chlamydial inclusions in clinically quiescent trachoma. West Afr. J. Med. 11, 55-61 (1992).
41. Thejls H, Gnarpe J, Lundkvist O, Heimer G, Larsson G, Victor A. Diagnosis and prevalence of persistent Chlamydia infection in infertile women: tissue culture, direct antigen detection, and serology. Fertil. Steril. 55, 304-310 (1991).
42. Dean D, Suchland RJ, Stamm WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J. Infect. Dis. 182, 909-916 (2000).
43. Smith A, Munoz B, Hsieh YH, Bobo L, Mkocha H, West S. OmpA genotypic evidence for persistent ocular Chlamydia trachomatis infection in Tanzania village women. Ophthalmic Epidemiol. 8, 127-135 (2001). (Pubitemid 32692557)
44. Holm SO, Jha HC, Bhatta RC et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull. World Health Organ. 79, 194-200 (2001). (Pubitemid 32246476)
45. Diamant J, Benis R, Schachter J et al. Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol. 8, 109-117 (2001). (Pubitemid 32692555)
46. Bain DL, Lietman T, Rasmussen S et al. Chlamydial genovar distribution after community wide antibiotic treatment. J. Infect. Dis. 184, 1581-1588 (2001). (Pubitemid 33139744)
47. Dawson CR, Schachter J. Should trachoma be treated with antibiotics? Lancet 359, 184-185 (2002).
48. Cohen CR, Brunham RC. Pathogenesis of Chlamydia induced pelvic inflammatory disease. Sex. Transm. Infect. 75, 21-24 (1999). (Pubitemid 29117476)
49. Ssemanda E, Munoz B, Harding-Esch E et al. Mass treatment with azithromycin for trachoma control: participation clusters in households. PLoS Negl. Trop. Dis. 4(2), e838 (2010).
50. de la Maza MA, de la Maza LM. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 13, 119-127 (1995).
51. Schachter J. Overview of Chlamydia trachomatis infection and the requirements for a vaccine. Rev. Infect. Dis. 7, 713-716 (1985).
52. Schachter J, Dawson CR. The epidemiology of trachoma predicts more blindness in the future. Sex. Transm. Dis. Suppl. 69, 55-62 (1990). (Pubitemid 20333088)
53. Brunham R, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5, 149-161 (2005). (Pubitemid 40208904)
54. Rockey D, Wang J, Lei L, Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev. Vaccines 8(10), 1365-1377 (2008).
55. Longbottom D, Livingstone M. Vaccination against chlamydial infections of man and animals. Vet. J. 171, 263-275 (2006). (Pubitemid 43257230)
56. Chalmers WS, Simpson J, Lee SJ, Baxendale W. Use of a live chlamydial vaccine to prevent ovine enzootic abortion. Vet. Rec. 141, 63-67 (1997). (Pubitemid 27353169)
57. Grayston JT, Woolridge RL, Wang S et al. Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan. Proc. Soc. Exp. Biol. Med. 112, 589-595 (1963).
58. Woolridge RL, Grayston JT, Chang IH, Yang CY, Cheng KH. Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan. Am. J. Ophthalmol. 63, 1650-1655 (1967).
59. Wang SP, Grayston JT, Alexander ER. Trachoma vaccine studies in monkeys. Am. J. Ophthalmol. 63, 1615-1620 (1967).
60. Clements C, Dhir S, Grayston J, Wang S. Long term follow-up study of a trachoma vaccine trial in villages of Northern India. Am. J. Ophthalmol. 87, 350-353 (1979). (Pubitemid 9111157)
61. Grayston JT, Wang SP, Yang YF, Woolridge RL. The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J. Exp. Med. 115, 1009-1022 (1962).
62. Bietti G, Guerra P, Vozza R et al. Results of large-scale vaccination against trachoma inEast Africa (Ethiopia) 1960-1965. Am. J. Ophthalmol. 61, 1010-1029 (1966).
63. Sowa S, Sowa J, Collier L, Blyth W. Trachoma vaccine field trials in The Gambia. J. Hyg. (Lond.) 67, 699-717 (1969).
64. Cochrane M, Armitage C, O'Meara C, Beagley K. Towards a Chlamydia trachomatis vaccine: how close are we? Future Microbiol. 5(12), 1833-1856 (2010).
65. de la Maza LM, Peterson EM. Vaccines for Chlamydia trachomatis infections. Curr. Opin. Investig. Drugs 3, 980-986 (2002). (Pubitemid 36266782)
66. Hafner L, Beagley K, Timms P. Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunol. 1, 116-130 (2008).
67. Hafner L, McNeilly C. Vaccines for Chlamydia infections of the female genital tract. Future Microbiol. 3(1), 67-77 (2008). (Pubitemid 351385952)
68. Igietseme JU, He Q, Eko FO et al. Development of vaccines to prevent chlamydial STDs. Mucosal Immunol. Update 13, 12-17 (2005).
69. Stephens RS. Chlamydial Genomics and Vaccine Antigen Discovery. J. Infect. Dis. 181, S521-S523 (2000). (Pubitemid 30416133)
70. Stephens RS, Lammel CJ. Chlamydia outer membrane protein discovery using genomics. Curr. Opin. Microbiol. 4, 16-20 (2001). (Pubitemid 32126891)
71. Kawa DE, Stephens RS. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J. Immunol. 168, 5184-5191 (2002). (Pubitemid 34495985)
72. Murdin AD, Dunn P, Sodoyer R et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J. Infect. Dis. 181, S544-S551 (2000). (Pubitemid 30416137)
73. Donati M, Sambri V, Comanducci M et al. DNA immunzation with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower tothe upper genital tract in C3H/HeN mice. Vaccine 21, 1089-1093 (2003). (Pubitemid 36142050)
74. Sharma J, Bosnic AM, Piper JM, Zhong G. Human antibody responses to a Chlamydia-secreted protease factor. Infect. Immun. 72, 7164-7171 (2004). (Pubitemid 39552387)
75. Belland RJ, Scidmore MA, Crane DD et al. Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. PNAS 98, 13984-13989 (2001). (Pubitemid 33116010)
76. Slepenkin A, de la Maza LM, Peterson EM. Interaction between components of theType III secretion system of Chlamydiaceae. J. Bacteriol. 187, 473-479 (2005). (Pubitemid 40096235)
77. Meoni E, Faenzi E, Frigimelica E et al. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect. Immun. 77, 4168-4176 (2009).
78. Follmann F, Olsen A, Jensen K et al. Antigenic profiling of a Chlamydia trachomatis gene-expression library. J. Infect. Dis. 197(6), 897-905 (2008). (Pubitemid 351417014)
79. Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect. Immun. 70, 2741-2751 (2002). (Pubitemid 34564127)
80. Loomis PW, Starnbach MN. T cell responses to Chlamydia trachomatis. Curr. Opin. Microbiol. 5, 87-91 (2002). (Pubitemid 34118163)
81. Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccine: strategies and status. BioDrugs 16, 19-35 (2002).
82. Igietseme JU, Eko FO, He Q et al. Delivery of Chlamydia vaccines. Expert Opin. Drug Deliv. 2, 549-562 (2005). (Pubitemid 41683227)
83. Rank RG. Models of immunity. In: Chlamydia: Intracellular Biology, Pathogenesis and Immunity. Stephens RS (Ed.), ASM Press, Washington, DC, USA 239-295 (1999).
84. Champion C, Kickhoefer V, Liu G et al. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS ONE 4, e5409 (2009).
85. Childs T, Webley W. In vitro assessment of chlamydial antigen display, delivery and processing by halobacterial gas vesicles. Presented at: 2011 ASM General Meeting, New Orleans, LA, USA, Session 197; Abstract 2215 (2011).
86. Stuart E, Morshed F, Sremac M, DasSarma S. Antigen presentation using novel particulate organelles from halophilic archaea. J. Biotechnol. 88, 119-128 (2001). (Pubitemid 32524248)
87. Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev. Vaccines 2(1), 129-146 (2003). (Pubitemid 36559946)
88. Pal S, Davis HL, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal challenge. Infect. Immun. 70, 4812-4817 (2002).
89. Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21, 1455-1465 (2003). (Pubitemid 36263187)
90. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17, 1075-1081 (1999). (Pubitemid 29533545)
91. Schijns VEJC. Antigen delivery systems and immunostimulation. Vet. Immunol. Immunopathol. 87, 195-198 (2002). (Pubitemid 34665238)
92. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vacines. Nat. Biotechnol. 16, 1025-1031 (1998). (Pubitemid 128723949)
93. Green BA, Baker SM. Recent advances and novel strategies in vaccine development. Curr. Opin. Microbiol. 5, 483-488 (2002).
94. Fletcher MA. Vaccine candidate in STD. Int. J. STD AIDS 12, 419-422 (2001).
95. Igietseme JU, Eko FO, He Q, Bandea C, Black C. Developing effective delivery systems for Chlamydia vaccines. Curr. Opin. Mol. Therapeutics 6, 182-194 (2004).
96. Glenn G. The 'perfect' adjuvant, a stronger voice. Expert Rev. Vaccines 10(4), 399-400 (2011).
97. Schijns VEJC, Lavelle E. Trends in vaccine adjuvants. Expert Rev. Vaccines 10(4), 539-550 (2011).
98. O'Hagan D, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10(4), 447-462 (2011).
99. Raghunandan R. Virus-like particles: innate immune stimulators. Expert Rev. Vaccines 10(4), 409-411 (2011).
100. Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev. Vaccines 10(4), 437-466 (2011).
101. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6, 723-739 (2007). (Pubitemid 47607848)
102. Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10(4), 471-486 (2011).
103. Tomai M, Vasilakos J. TLR-7 and TLR-8 agonists as vaccine adjuvants. Expert Rev. Vaccines 10(4), 405-407 (2011).
104. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10(4), 499-511 (2011).
105. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 283, 1335-1339 (1999).
106. Segal B, Chang J, Shevach E. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164(11), 5683-5688 (2000). (Pubitemid 30389809)
107. Petrovsy N, Cooper P. Carbohydrate-based immune adjuvants. Expert Rev. Vaccines 10(4), 523-537 (2011).
108. Wu H-Y, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 16, 187-201 (1997). (Pubitemid 27294589)
109. Kelly KA, Rank RG. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect. Immun. 65, 5198-5208 (1997). (Pubitemid 27513570)
110. Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses 13, 945-952 (1997). (Pubitemid 27334700)
111. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune respose against a genital challenge. Infect. Immun. 69, 6240-6247 (2001). (Pubitemid 32885187)
112. He Q, Martinez-Sobrido L, Eko FO et al. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology 122, 28-37 (2007). (Pubitemid 47222592)
113. Li W, Murthy A, Guentzel M et al. Antigen-specific CD4+ T cells produce sufficient IFN-g to mediate robust protective immunity against genital Chlamydia muridarum infection J. Immunol. 180, 3375-3382 (2008).
114. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with an acellular vaccine consisting of the outer membranecomplex of Chlamydia trachomatis induces protection against a genital challenge. Infect. Immun. 65, 3361-3369 (1997). (Pubitemid 27342422)
115. Stephens R. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol. 11, 44-51 (2003). (Pubitemid 36084355)
116. Gondek D, Roan N, Starnbach M. T cell responses in the absence of IFN-g exacerbate uterine infection with Chlamydia trachomatis. J. Immunol. 183, 1313-1319 (2009).
117. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol. Immunol. 51, 1139-1147 (2007).
118. Ley K, Smith E, MA S. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol. Res. 34, 229-242 (2006). (Pubitemid 44195938)
119. Byrne G. Chlamydia trachomatis strains and virulence: rethinking links to infection prevalence and disease severity. J. Infect. Dis. 201, S126-S133 (2010).
120. Bachmaier K, Penninger J. Chlamydia and antigenic mimicry. Curr. Top. Microbiol. Immunol. 296, 153-163 (2005). (Pubitemid 41667266)
121. Swanborg R, Boros D, Whittum-Hudson J, Hudson A. Molecular mimicry and horror autotoxicus: do chlamydial infections elicit autoimmunity? Expert Rev. Mol. Med. 8(29), 1-23 (2006). (Pubitemid 44848624)
122. Cragnolini J, García-Medel N, de Castro J. Endogenous processing and presentation of T-cell epitopes from Chlamydia trachomatis with relevance in HLA-B27-associated reactive arthritis. Mol. Cell Proteomics 8, 1850-1859 (2009).